On Thursday 21 October 2021 at 11.40 CET, CEO Mikael Lindstam will present the latest development in Aptahem and the lead candidate Apta-1 at the BioStock Life Science Summit. The event can be followed online via the link: BioStock...
Read MoreAptahem AB (publ) announces today that the Turkish patent office has approved the patent application as the first validated country in Europe. The patent was published with the patent number TR2021/013877 T4. The approval by the Turkish patent office...
Read MoreAptahem AB develops drugs for the treatment of acute life-threatening conditions where Apta-1, the company’s main candidate, is under development and intended as an emergency drug to prevent the occurrence of organ and tissue damage in patients suffering from...
Read MoreAptahem can today announce that further studies with Örebro University on Apta-1 show strong evidence in its features on the coagulation and inflammation by a unique modulation of Thrombin. This mechanism of action distinctly differs from current clinical used...
Read MoreAptahem AB (publ) announces today that the company has received patent protection in USA for patent family 2 from the United States Patent and Trademark Office (USPTO). The approval follows the previous preliminary approval from USPTO which was communicated...
Read MoreAptahem AB (publ) announces today that the European Patent Office (EPO) has approved the EU patent application EP 18783424.7 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties. The approval follows the previous provisional approval by...
Read MoreAptahem AB (publ) announces today that the GLP (Good Laboratory Practice) toxicology and safety studies preliminary show positive results. The studies are the final part of the preclinical program before an application to start clinical studies can be filed....
Read MoreBioStock published an article on 12 July 2021 about Aptahem, which can be read in full below. During 2021, sepsis company Aptahem has taken several steps to prepare for its first clinical evaluation of its leading drug candidate Apta-1....
Read MoreAptahem AB (publ) announces today that the company has received information that the European Patent Office (EPO) has issued an Intention to Grant of the EU patent application EP 18783424.7 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant...
Read MoreBioStock published an article on 1 July 2021 about Aptahem, which can be read in full below. Since 2019, Aptahem has collaborated with the Cardiovascular Research Centre (CVRC) at Örebro University to better understand certain mechanisms behind Apta-1’s effect....
Read More